Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bicycle Therapeutics Ltd (BCYC)
NASDAQ:BCYC
RESEARCH TOOLSreports
Bicycle Therapeutics (BCYC) Stock Price & Analysis
311 Followers
BCYC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.54 - $27.50
Previous Close$19.58
Volume225.72K
Average Volume (3M)328.07K
Market Cap
$881.12M
Enterprise Value$394.80M
Total Cash (Recent Filing)$526.40M
Total Debt (Recent Filing)$40.08M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Aug 01, 2024EPS Estimate
-$1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.46
Shares Outstanding42,779,030
10 Day Avg. Volume295,723
30 Day Avg. Volume328,067
Standard Deviation0.19
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.37
Price to Sales (P/S)146.62
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.64
Enterprise Value/Gross Profit14.64
Enterprise Value/Ebitda-2.33
Forecast
1Y Price Target
$43.00Price Target Upside112.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bicycle Therapeutics News
PremiumCompany Announcements
Power Pedal: How Insider Voting Clout Could Sway Bicycle Therapeutics’ Future
PremiumCompany Announcements
Bicycle Therapeutics Announces Board Reshuffle and New Financial Agreement
Bulls Say, Bears Say
Bulls Say
Clinical PerformanceBT8009 showed a 38% therapy response rate in clinical data, indicating promising efficacy.
Financial HealthBicycle reported $19.5M in collaboration revenues, significantly surpassing analyst estimates.
Safety ProfileBT8009 demonstrated an improved safety profile with only 15% of patients experiencing grade 3 or higher treatment-related adverse events, compared to 34% for Padcev.
Bears Say
Clinical TrialsBT8009 demonstrated an overall response rate of 33% compared to 68% in the Padcev + pembro Phase 3 trial, indicating room for improvement.
Financial PerformanceThe price target has been lowered to $32 from $44 based on a discounted earnings per share and revenue multiple analysis.
Regulatory ApprovalThe FDA approved the combination of Padcev and pembro for front-line treatment of locally advanced or mUC, showing a higher ORR of 68% in the Phase 3 trial compared to BT8009's 33%.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
BCYC FAQ
What was Bicycle Therapeutics Ltd’s price range in the past 12 months?
Bicycle Therapeutics Ltd lowest stock price was $12.54 and its highest was $27.50 in the past 12 months.
What is Bicycle Therapeutics Ltd’s market cap?
Currently, no data Available
When is Bicycle Therapeutics Ltd’s upcoming earnings report date?
Bicycle Therapeutics Ltd’s upcoming earnings report date is Aug 01, 2024 which is in 27 days.
How were Bicycle Therapeutics Ltd’s earnings last quarter?
Bicycle Therapeutics Ltd released its earnings results on May 02, 2024. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$1.251 by $0.631.
Is Bicycle Therapeutics Ltd overvalued?
According to Wall Street analysts Bicycle Therapeutics Ltd’s price is currently Undervalued.
Does Bicycle Therapeutics Ltd pay dividends?
Bicycle Therapeutics Ltd does not currently pay dividends.
What is Bicycle Therapeutics Ltd’s EPS estimate?
Bicycle Therapeutics Ltd’s EPS estimate is -$1.15.
How many shares outstanding does Bicycle Therapeutics Ltd have?
Bicycle Therapeutics Ltd has 45,001,175 shares outstanding.
What happened to Bicycle Therapeutics Ltd’s price movement after its last earnings report?
Bicycle Therapeutics Ltd reported an EPS of -$0.62 in its last earnings report, beating expectations of -$1.251. Following the earnings report the stock price went up 2.025%.
Which hedge fund is a major shareholder of Bicycle Therapeutics Ltd?
Among the largest hedge funds holding Bicycle Therapeutics Ltd’s share is Baker Bros Advisors LP. It holds Bicycle Therapeutics Ltd’s shares valued at 123M.
---
Bicycle Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.00 (112.77% Upside)
$43.00 (112.77% Upside)
Blogger Sentiment
Bullish
BCYC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $171.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 10.1%
Last 30 Days ▲ 10.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.20%
12-Months-Change
Fundamentals
Return on Equity
-56.21%
Trailing 12-Months
Asset Growth
27.60%
Trailing 12-Months
Company Description
Bicycle Therapeutics Ltd
Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
---
BCYC Stock 12 Month Forecast
Average Price Target
$43.00
▲(112.77% Upside)
Technical Analysis
Best Analysts Covering BCYC
1 Year
1 Year Success Rate
10/17 ratings generated profit
1 Year Average Return
+35.48%
reiterated a buy rating 2 months ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +35.48% per trade.
---